Mineralys Therapeutics, Inc.

RADNOR, PA · Founded 2019 · CIK 0001933414 · Biotech · Public

Aldosterone antagonist therapeutics for hypertension and chronic kidney disease

mineralystx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$118M
1 Form D · Jun 2022
52 months since last filing
Contracts
—
No federal contracts on record
Patents
12
0 granted · 12 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$117,999,994
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2813Interius BioTherapeutics—$118M
2814TAMBO, INC.——
2815Diapin Therapeutics LLC——
2816Mineralys Therapeutics, Inc.—$118M
2817LYST THERAPEUTICS LLC——
2818Relation Therapeutics—$116M
2819STEL Technologies, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Srinivas AkkarajuDirector
  • Alexander AsamDirector
  • Jon CongletonDirector · Executive Officer
  • Derek DiRoccoDirector
  • Adam LevyExecutive Officer
  • Olivier LitzkaDirector
  • Takeshi TakahashiDirector
  • Brian Taylor SlingsbyDirector

Patents

USPTO · 0 granted of 12
  • Methods Of Treating Hypertension With A Combination Of An Aldosterone Synthase Inhibitor And A Diureticapplication
  • Methods Of Treating Hypertension In Obese Subjectsapplication
  • CYP11B2 Beta Hydroxylase Inhibitors For Hypertensionapplication
  • Methods Of Treating Chronic Kidney Disease (ckd) Or Ckd And Hypertension With Lorundrostat, Or A Combination Of Lorundrostat And A SGLT2 Inhibitorapplication
  • Methods Of Treating Hypertension In Obese Subjectsapplication
  • Methods Of Treating Hypertension With A Combination Of An Aldosterone Synthase Inhibitor And A Diureticapplication
  • CYP11B2 Beta Hydroxylase Inhibitors For Hypertensionapplication
  • CYP11B2 Beta Hydroxylase Inhibitors For Hypertensionapplication
  • Methods Of Treating Hypertension With A Combination Of Lorundrostat And Two Or More Anti-hypertensive Medicationsapplication
  • Methods Of Treating Chronic Kidney Disease (ckd) Or Ckd And Hypertension With Lorundrostat, Or A Combination Of Lorundrostat And A SGLT2 Inhibitorapplication
  • Process For Producing Triazine Compoundapplication
  • Methods Of Treating Hypertension With A Combination Of Lorundrostat And Two Or More Anti-hypertensive Medicationsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.